Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/122826
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Relaxin reduces endothelium-derived vasoconstriction in hypertension: revealing new therapeutic insights
Author: Leo, C.H.
Ng, H.H.
Marshall, S.A.
Jelinic, M.
Rupasinghe, T.
Qin, C.
Roessner, U.
Ritchie, R.H.
Tare, M.
Parry, L.J.
Citation: British Journal of Pharmacology, 2019; 177(1):1-17
Publisher: Wiley
Issue Date: 2019
ISSN: 0007-1188
1476-5381
Statement of
Responsibility: 
Chen Huei Leo, Hooi Hooi Ng, Sarah A. Marshall, Maria Jelinic, Thusitha Rupasinghe ... Laura J. Parry ... et al.
Abstract: BACKGROUND AND PURPOSE:Endothelium-derived vasoconstriction is a hallmark of vascular dysfunction in hypertension. In some cases, an overproduction of endothelium-derived prostacyclin (PGI2 ) can cause contraction rather than relaxation. Relaxin is well known for its vasoprotective actions, but the possibility that this peptide could also reverse endothelium-derived vasoconstriction has never been investigated. We tested the hypothesis that short-term relaxin treatment mitigates endothelium-derived vasoconstriction in spontaneously hypertensive rats (SHR). EXPERIMENTAL APPROACH:Male Wistar Kyoto rats (WKY) and SHR were subcutaneously infused with either vehicle (20 mmol·L-1 sodium acetate) or relaxin (13.3 μg·kg-1 ·hr-1 ) using osmotic minipumps for 3 days. Vascular reactivity to the endothelium-dependent agonist ACh was assessed in vitro by wire myography. Quantitative PCR and LC-MS were used to identify changes in gene expression of prostanoid pathways and PG production, respectively. KEY RESULTS:Relaxin treatment ameliorated hypertension-induced endothelial dysfunction by increasing NO-dependent relaxation and reducing endothelium-dependent contraction. Notably, short-term relaxin treatment up-regulated mesenteric PGI2 receptor (IP) expression, permitting PGI2 -IP-mediated vasorelaxation. In the aorta, reversal of contraction was accompanied by suppression of the hypertension-induced increase in prostanoid-producing enzymes and reduction in PGI2 -evoked contractions. CONCLUSIONS AND IMPLICATIONS:Relaxin has region-dependent vasoprotective actions in hypertension. Specifically, relaxin has distinct effects on endothelium-derived contracting factors and their associated vasoconstrictor pathways in mesenteric arteries and the aorta. Taken together, these observations reveal the potential of relaxin as a new therapeutic agent for vascular disorders that are associated with endothelium-derived vasoconstriction including hypertension.
Keywords: Mesenteric Arteries
Endothelium, Vascular
Animals
Rats, Inbred SHR
Rats, Inbred WKY
Rats
Hypertension
Relaxin
Vasoconstriction
Dose-Response Relationship, Drug
Male
Description: First published: 03 September 2019
Rights: © 2019 The British Pharmacological Society.
DOI: 10.1111/bph.14858
Grant ID: http://purl.org/au-research/grants/nhmrc/1059960
Published version: http://dx.doi.org/10.1111/bph.14858
Appears in Collections:Aurora harvest 8
Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.